Site updated at Wednesday, 22 June 2016

Living with Dementia

Psychotic Symptoms

Acadia redesigns study on Parkinson’s psychosis drug

Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson’s disease patients, and that it plans to conduct an identical study to win regulatory approval.

The redesigned study will include only patients from North America, and will exclude mildly psychotic patients, Acadia CEO Uli Hacksell said at… Acadia redesigns study on Parkinson’s psychosis drug   

Enid and George - Life with dementia

lipid-lowering drugs1 - long-term dementia1 - cognitive deterioration2 - postoperative cognitive dysfunction1 - fatal neurological disorder1 - hallucinoses1 - dopamine deficiency1 - dementia care program1 - heart health risk1 - signs of alzheimers1 - cardiac arrest1 - degenerative dementia2 - risk of dementia12 - multiple system atrophy1 - developing dementia2 - risk of developing parkinson's1 - amyloid β1 - beta-amyloid peptides1 - uncategorized1 - marijuana1 - arteriosclerosis2 - alzheimer’s disease8 - physical weakness1 - thinking abilities1 - apolipoprotein e2 - deficiency of thiamine1 - entorhinal cortex1 - dopaminergic neurons1 - alpha-synuclein7 - beta-amyloid protein1 -